Overview

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Status:
Completed

Trial end date:
2016-09-16

Target enrollment:

Participant gender:

Summary

This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).

Phase:

Phase 4

Details

Lead Sponsor:

Forest Laboratories

Treatments:

Levomilnacipran
Milnacipran